BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Hsieh as executive director of its Los Angeles office.  Hsieh was president and CEO of Meditope Biosciences Inc. BC...
BioCentury | Jan 12, 2015
Company News

Meditope management update

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies, Cancer Transitioned: Bob McKenzie to EVP of business development, while remaining a director WIR Staff cancer...
BioCentury | Nov 18, 2013
Emerging Company Profile

Meditope: Keyhole conjugation

...warhead should be attached to produce a homogeneous product (see BioCentury, Aug. 19) . Meditope's meditope-enabled...
...known as a meditope - is able to bind non-covalently. Williams, a member of Meditope's...
...South San Francisco, Calif. Thomas Jefferson University , Philadelphia, Pa. Sidebars Meditope Biosciences Inc. Pasadena, Calif. Technology: Meditope-enabled...
BioCentury | Oct 31, 2013
Cover Story

Building meditope-enabled mAbs

...crystal structure of the Erbitux Fab domain in complex with meditope peptides showed that the meditope-binding...
...cancer. Meditope benefits Williams said that the meditope platform obviates the need to reengineer a meditope-enabled...
...been exclusively licensed to Meditope Biosciences. Hsieh said that Meditope is seeking deals to generate meditope-enabled...
BioCentury | Oct 31, 2013
Distillery Techniques

Technology: Drug platforms

...the Fab framework of Erbitux that can noncovalently bind to an engineered peptide called a meditope...
...and evaluating the use of meditope-enabled mAbs for research and therapeutic applications. Meditope Biosciences Inc. is developing meditope-enabled...
...Patent applications filed by City of Hope; exclusively licensed to Meditope; available for partnering through Meditope...
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

...with improved stability. Keyhole specificity A variation on the site-specific conjugation approach is Meditope Biosciences Inc. 's meditope-enabled...
...a specific small peptide is able to non-covalently bind - similar to a ligand-receptor interaction. Meditope...
...ADCs with payload linked to disulfide bonds of mAb for site- specific conjugation Preclin Meditope Biosciences Inc. Meditope-enabled...
BioCentury | Jul 29, 2013
Company News

Meditope management update

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies Hired: Elisabeth Gardiner as CSO, formerly director of physiology at aTyr Pharma Inc. WIR Staff...
BioCentury | Jul 29, 2013
Financial News

Meditope completes venture financing

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies, Cancer Date completed: 7/26/13 Type: Venture financing Raised: $3.6 million Investors: Angel investors WIR Staff cancer...
BioCentury | Jul 27, 2013
Financial News

Meditope raises $3.6M in series A

...is developing a technology to link antibodies to payloads without the need for chemical conjugation. Meditope...
BioCentury | Nov 2, 2009
Clinical News

Myderison tolperisone regulatory update

EMEA's CHMP said that after an arbitration procedure following a disagreement among EU member states the agency concluded that the benefits did not outweigh the risks for Meditop's Myderison tolperisone to treat skeletal muscle spasticity....
Items per page:
1 - 10 of 10
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Hsieh as executive director of its Los Angeles office.  Hsieh was president and CEO of Meditope Biosciences Inc. BC...
BioCentury | Jan 12, 2015
Company News

Meditope management update

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies, Cancer Transitioned: Bob McKenzie to EVP of business development, while remaining a director WIR Staff cancer...
BioCentury | Nov 18, 2013
Emerging Company Profile

Meditope: Keyhole conjugation

...warhead should be attached to produce a homogeneous product (see BioCentury, Aug. 19) . Meditope's meditope-enabled...
...known as a meditope - is able to bind non-covalently. Williams, a member of Meditope's...
...South San Francisco, Calif. Thomas Jefferson University , Philadelphia, Pa. Sidebars Meditope Biosciences Inc. Pasadena, Calif. Technology: Meditope-enabled...
BioCentury | Oct 31, 2013
Cover Story

Building meditope-enabled mAbs

...crystal structure of the Erbitux Fab domain in complex with meditope peptides showed that the meditope-binding...
...cancer. Meditope benefits Williams said that the meditope platform obviates the need to reengineer a meditope-enabled...
...been exclusively licensed to Meditope Biosciences. Hsieh said that Meditope is seeking deals to generate meditope-enabled...
BioCentury | Oct 31, 2013
Distillery Techniques

Technology: Drug platforms

...the Fab framework of Erbitux that can noncovalently bind to an engineered peptide called a meditope...
...and evaluating the use of meditope-enabled mAbs for research and therapeutic applications. Meditope Biosciences Inc. is developing meditope-enabled...
...Patent applications filed by City of Hope; exclusively licensed to Meditope; available for partnering through Meditope...
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

...with improved stability. Keyhole specificity A variation on the site-specific conjugation approach is Meditope Biosciences Inc. 's meditope-enabled...
...a specific small peptide is able to non-covalently bind - similar to a ligand-receptor interaction. Meditope...
...ADCs with payload linked to disulfide bonds of mAb for site- specific conjugation Preclin Meditope Biosciences Inc. Meditope-enabled...
BioCentury | Jul 29, 2013
Company News

Meditope management update

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies Hired: Elisabeth Gardiner as CSO, formerly director of physiology at aTyr Pharma Inc. WIR Staff...
BioCentury | Jul 29, 2013
Financial News

Meditope completes venture financing

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies, Cancer Date completed: 7/26/13 Type: Venture financing Raised: $3.6 million Investors: Angel investors WIR Staff cancer...
BioCentury | Jul 27, 2013
Financial News

Meditope raises $3.6M in series A

...is developing a technology to link antibodies to payloads without the need for chemical conjugation. Meditope...
BioCentury | Nov 2, 2009
Clinical News

Myderison tolperisone regulatory update

EMEA's CHMP said that after an arbitration procedure following a disagreement among EU member states the agency concluded that the benefits did not outweigh the risks for Meditop's Myderison tolperisone to treat skeletal muscle spasticity....
Items per page:
1 - 10 of 10